Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hypophosphatemia is a common and potentially serious complication during continuous renal replacement therapy. Studies indicate that up to 80% of patients undergoing CRRT develop hypophosphatemia. Therefore, phosphate supplementation is required for the vast majority of CRRT patients, particularly within the initial 24 hours of treatment. This retrospective cohort study conducted at our center evaluated key factors influencing hypophosphatemia occurrence and its impact on patient outcomes among critically ill adults undergoing CRRT for over 48 hours.
Patients were divided into the hypophosphatemia group and non-hypophosphatemia group based on a serum phosphorus level <0.81mmol/L after initiation of continuous renal replacement therapy. Comparison of differences in relevant indicators between the two groups of patients before and during CRRT. Additionally, patients were categorized into a 28-day mortality group and a 28-day survival group based on their prognosis following initiation of CRRT. Differences in relevant indicators between the two groups were compared both before and during CRRT treatment.
A total of 100 critically ill patients were included.Hypoplasminemia occurred in 71% of patients during CRRT.Compared with the non-hypophosphatemic group, patients in the hypophosphatemic group exhibited significantly lower serum phosphorus levels before CRRT and 24 hours after CRRT, longer CRRT duration, elevated pH during CRRT, and reduced diastolic blood pressure. Multivariate logistic regression analysis revealed that lower serum phosphorus levels within 24 hours after CRRT initiation, lower diastolic blood pressure during CRRT, and longer CRRT duration were independent risk factors for hypophosphatemia in critically ill patients undergoing CRRT. Within 28 days of CRRT initiation, 68 patients died. Compared with the non-hypophosphatemic group, patients with hypophosphatemia exhibited a significantly higher mortality rate. Kaplan-Meier survival curves demonstrated that patients with hypophosphatemia had a poorer prognosis than those without hypophosphatemia, with a statistically significant difference. Compared with the survival group, patients in the mortality group had significantly higher age and C-reactive protein levels during dialysis, while serum phosphorus levels at 24 hours post-dialysis were significantly lower, with statistically significant differences. Multivariate Cox proportional hazards regression analysis revealed that a high APACHE II score was an independent risk factor for 28-day mortality in critically ill patients receiving CRRT.
Figure 1. Kaplan-Meier Survival Curve Comparing 28-Day Survival Outcomes Among Critically Ill Patients Undergoing CRRT at Different Serum Phosphorus Levels
Table 1. Multifactorial Cox Proportional Hazards Regression Model Analysis of Risk Factors Affecting the 28-Day Prognosis of Critically Ill Patients Undergoing CRRT
Hypophosphatemia occurs frequently in patients undergoing CRRT and is associated with clinical prognosis. For critically ill patients requiring CRRT, particularly those with low pre-dialysis serum phosphorus levels and prolonged CRRT duration, measures should be implemented to prevent hypophosphatemia.
